Company intelligence / Profile preview
Illudent Therapeutics
San Diego, California, United Statesilludent.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Illudent Therapeutics is developing ITX-121, a small molecule designed to selectively kill cancer cells deficient in the nucleotide-excision repair pathway. The therapy is being advanced as a precision medicine for multiple solid tumor types and aims to be first-in-class for this patient population. Patient selection will be based on biomarkers. No published clinical results are available yet; the program appears preclinical or at an early clinical development stage.
- Therapeutic areas
- Oncology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
None publicly disclosed as of May 2025.
Beyond the preview
Go deeper on Illudent Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Illudent Therapeutics.